Literature DB >> 7510667

A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides.

M Trautmann1, K Vogt, C Hammack, A S Cross.   

Abstract

A hybridoma secreting a monoclonal antibody (MAb) directed against Klebsiella lipopolysaccharide (LPS) was derived from spleen cells of mice immunized a smooth, nonencapsulated Klebsiella strain (Friedländer 201; serogroup O1). The MAb, called V/9-5 (immunoglobulin G2a), cross-reacted with LPS preparations produced from reference strains for the Klebsiella O serogroups O1, O2ab, O2ac, O3, O4, O5, and O12. Furthermore, the MAb reacted with LPSs from serogroup reference strains O6/O8, O9, and O11, which are regarded as being identical to O1, O2, and O4, respectively. When testing the supernatant of clinically isolated Klebsiella strains by means of an inhibition enzyme-linked immunosorbent assay, we found that 86 (92.4%) of 93 Klebsiella pneumoniae subsp. pneumoniae isolates and 24 (96.0%) of 25 K. oxytoca isolates harbored the cross-reactive epitope. By contrast, two laboratory strains of K. pneumoniae subsp. rhinoscleromatis did not react with MAb V/9-5. The MAb proved to be specific for the genus Klebsiella, since it did not react with any of a total of 73 strains belonging to other gram-negative bacterial genera. In conjunction with other LPS-specific MAbs, MAb V/9-5 might become a useful reagent for rapid identification of klebsiellae in clinical specimens. Furthermore, the epitope recognized by MAb V/9-5 might serve as a target epitope for the production of human MAbs for immunotherapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510667      PMCID: PMC186270          DOI: 10.1128/iai.62.4.1282-1288.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Human monoclonal antibodies specific for capsular polysaccharides of Klebsiella recognize clusters of multiple serotypes.

Authors:  A B Lang; U Bruderer; G Senyk; T L Pitt; J W Larrick; S J Cryz
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

Review 2.  Klebsiella pulmonary infections: occurrence at one medical center and review.

Authors:  J L Carpenter
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

3.  Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia.

Authors:  T K Held; M Trautmann; M E Mielke; H Neudeck; S J Cryz; A S Cross
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

4.  Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae.

Authors:  E Mandine; M F Salles; R Zalisz; M Guenounou; P Smets
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

5.  Expression of two structurally distinct D-galactan O antigens in the lipopolysaccharide of Klebsiella pneumoniae serotype O1.

Authors:  C Whitfield; J C Richards; M B Perry; B R Clarke; L L MacLean
Journal:  J Bacteriol       Date:  1991-02       Impact factor: 3.490

6.  Surface exposure of O1 serotype lipopolysaccharide in Klebsiella pneumoniae strains expressing different K antigens.

Authors:  J M Tomás; S Camprubi; S Merino; M R Davey; P Williams
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

7.  Structure of the O-specific polysaccharide chain from Klebsiella pneumoniae O1K2 (NCTC 5055) lipopolysaccharide.

Authors:  O Kol; J M Wieruszeski; G Strecker; J Montreuil; B Fournet; R Zalisz; P Smets
Journal:  Carbohydr Res       Date:  1991-09-18       Impact factor: 2.104

8.  Human vaccination with Escherichia coli J5 mutant induces cross-reactive bactericidal antibody against Neisseria gonorrhoeae lipooligosaccharide.

Authors:  P A Dale; D P McQuillen; S Gulati; P A Rice
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

9.  Structural analysis of the O-antigen side chain polysaccharides in the lipopolysaccharides of Klebsiella serotypes O2(2a), O2(2a,2b), and O2(2a,2c).

Authors:  C Whitfield; M B Perry; L L MacLean; S H Yu
Journal:  J Bacteriol       Date:  1992-08       Impact factor: 3.490

10.  Eight lipooligosaccharides of Neisseria meningitidis react with a monoclonal antibody which binds lacto-N-neotetraose (Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc).

Authors:  C M Tsai; C I Civin
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

View more
  7 in total

1.  O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections.

Authors:  M Trautmann; M Ruhnke; T Rukavina; T K Held; A S Cross; R Marre; C Whitfield
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

2.  Structure of the core oligosaccharide in the serotype O8 lipopolysaccharide from Klebsiella pneumoniae.

Authors:  W B Severn; R F Kelly; J C Richards; C Whitfield
Journal:  J Bacteriol       Date:  1996-03       Impact factor: 3.490

3.  Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection.

Authors:  T Rukavina; B Tícac; M Susa; N Jendrike; S Jonjíc; P Lucin; R Marre; M Doríc; M Trautmann
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

4.  Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains.

Authors:  T K Held; N R Jendrike; T Rukavina; R Podschun; M Trautmann
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

5.  Progress towards the development of Klebsiella vaccines.

Authors:  Myeongjin Choi; Sharon M Tennant; Raphael Simon; Alan S Cross
Journal:  Expert Rev Vaccines       Date:  2019-06-28       Impact factor: 5.217

6.  Proinflammatory cytokines in antilipopolysaccharide immunity against Klebsiella infections.

Authors:  Tomislav Rukavina; Vanja Vasiljev; Brigita Ticac
Journal:  Mediators Inflamm       Date:  2005-06-09       Impact factor: 4.711

Review 7.  Klebsiella pneumoniae capsule polysaccharide as a target for therapeutics and vaccines.

Authors:  Clement Opoku-Temeng; Scott D Kobayashi; Frank R DeLeo
Journal:  Comput Struct Biotechnol J       Date:  2019-10-25       Impact factor: 7.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.